Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
Healthcare | Biotechnology | USA
statements
IndexS&P 500 P/E72.83 EPS (ttm)2.52 Insider Own0.10% Shs Outstand259.21M Perf Week5.73%
Market Cap47.57B Forward P/E29.60 EPS next Y6.20 Insider Trans-51.48% Shs Float256.70M Perf Month3.04%
Income655.00M PEG1.54 EPS next Q1.13 Inst Own97.90% Short Float1.73% Perf Quarter4.73%
Sales3.45B P/S13.77 EPS this Y99.10% Inst Trans-0.05% Short Ratio3.77 Perf Half Y4.65%
Book/sh19.79 P/B9.27 EPS next Y34.98% ROA36.20% Target Price216.40 Perf Year2.59%
Cash/sh15.24 P/C12.04 EPS next 5Y47.38% ROE51.70% 52W Range151.80 - 195.81 Perf YTD10.75%
Dividend- P/FCF33.66 EPS past 5Y23.90% ROI11.20% 52W High-6.27% Beta1.43
Dividend %- Quick Ratio3.60 Sales past 5Y20.30% Gross Margin86.60% 52W Low20.90% ATR4.34
Employees2500 Current Ratio3.70 Sales Q/Q-32.40% Oper. Margin25.50% RSI (14)64.90 Volatility2.74% 2.36%
OptionableYes Debt/Eq0.12 EPS Q/Q-36.10% Profit Margin64.10% Rel Volume0.92 Prev Close176.23
ShortableYes LT Debt/Eq0.11 EarningsOct 30 AMC Payout0.00% Avg Volume1.18M Price183.53
Recom2.00 SMA206.84% SMA504.15% SMA2002.86% Volume1,088,594 Change4.14%
Oct-17-19Resumed BofA/Merrill Buy $220
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-01-19Downgrade Needham Buy → Hold
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Oct-21-19 10:31PM  Dow Jones Futures: Stock Market Rally Nears Key Levels; Cadence Design, Vertex, Stamps.com, Opioid Settlement Make News Investor's Business Daily
04:07PM  Vertex to Announce Third-Quarter 2019 Financial Results on October 30 Business Wire
03:55PM  FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation Business Wire
03:53PM  UPDATE 2-Vertex prices cystic fibrosis combo treatment at $311,000/yr Reuters
03:16PM  Vertex's drug for almost all cystic fibrosis patients approved five months early American City Business Journals
03:15PM  FDA approves Vertex Pharma's combo treatment for cystic fibrosis Reuters
01:26PM  Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor) Business Wire
10:24AM  Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings? Zacks
09:33AM  Alexion Gets FDA Approval for Label Expansion of Ultomiris Zacks
07:56AM  5 Large-Cap Stocks Set to Beat Earnings Estimates This Month Zacks
Oct-19-19 07:29PM  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia Business Wire
Oct-18-19 08:54AM  What's in Store for Align Technology's (ALGN) Q3 Earnings? Zacks
08:37AM  Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age Business Wire
Oct-17-19 12:03PM  Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings? Zacks
11:33AM  The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences Zacks
10:41AM  4 Biotech Stocks That Are Set to Rally, Analyst Says Barrons.com
07:22AM  What's in Store for Edwards Lifesciences' (EW) Q3 Earnings? Zacks
Oct-16-19 02:13PM  Top Research Reports for Southern, Applied Materials & Vertex Zacks
10:33AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
10:13AM  CRISPR Therapeutics Enters New License Agreement, Shares Up Zacks
Oct-15-19 10:37AM  Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings? Zacks
Oct-14-19 04:59PM  Selling Tools to Miners: The Stocks That Can Profit on Biotech and Prosthetics GuruFocus.com
11:43AM  Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings? Zacks
10:10AM  Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive? Zacks
09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Oct-11-19 12:56PM  10 High-Quality, High-Growth Stocks to Buy Kiplinger
Oct-10-19 06:31PM  Were Hedge Funds Right About Dumping Vertex Pharmaceuticals Incorporated (VRTX)? Insider Monkey
Oct-09-19 03:41PM  A Look At The Fair Value Of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Simply Wall St.
Oct-08-19 11:46AM  7 Underpriced Stocks With Biggest Upside as Market Stages 4Q Rally Investopedia
Oct-04-19 09:20AM  Check Out These 5 Fast-Growing Stocks to Buy InvestorPlace
Oct-03-19 11:21AM  Kymera tripling HQ with move out of Cambridge American City Business Journals
Oct-02-19 02:52PM  How a new deal could mean up to $700M for a Durham drugmaker American City Business Journals
09:29AM  Vertex Enters Into Collaboration With Privately-Held Ribometrix Zacks
Oct-01-19 08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
08:00AM  Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer Business Wire
06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
08:00AM  Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics Business Wire
06:21AM  CRISPR gene editing startup Beam Therapeutics plans $100M IPO American City Business Journals
Sep-27-19 09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Sep-20-19 08:31AM  3 Big Biotech Stocks Worth Adding to Your Portfolio Now Zacks
Sep-17-19 10:14AM  The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial Zacks
Sep-16-19 02:25PM  Top Stock Reports for Celgene, Sinopec & HSBC Zacks
Sep-13-19 03:44PM  How Much Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Insiders Taking Off The Table? Simply Wall St.
11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
Sep-12-19 11:43AM  Vertex strikes deal to sell cystic fibrosis drugs in Scotland, but British debate continues American City Business Journals
04:06AM  Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) Business Wire
Sep-11-19 09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Sep-10-19 08:30AM  Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11 Business Wire
Sep-04-19 09:39PM  Dont Blink or Youll Miss Vertexs Next Move, And Its Bound to Be a Good One Motley Fool
06:57PM  Wall Street Green on Wednesday GuruFocus.com
10:32AM  Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M Zacks
10:02AM  Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
08:00AM  Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff Motley Fool
Sep-03-19 09:33AM  Buy Vertex Pharmaceuticals Stock Because of Its Emerging Pipeline Barrons.com
09:15AM  Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M Benzinga
09:06AM  Vertex snaps up Cambridge diabetes startup Semma for $950M American City Business Journals
08:33AM  UPDATE 1-Vertex to buy cell therapy developer Semma for $950 mln Reuters
Sep-01-19 09:00AM  3 Healthcare Stocks That Have a Killer Advantage Motley Fool
Aug-31-19 02:37PM  Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More Benzinga
Aug-29-19 05:50PM  Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know Zacks
07:39AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Aug-28-19 01:31PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
10:02AM  Moving Average Crossover Alert: Vertex Pharmaceuticals Zacks
Aug-27-19 08:44AM  3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands InvestorPlace
Aug-26-19 09:30AM  Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year? Zacks
Aug-22-19 11:55AM  The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron Zacks
07:35AM  Should You Worry About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Salary Level? Simply Wall St.
Aug-21-19 11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
Aug-20-19 07:15PM  Vertex Pharmaceuticals Inc (VRTX) EVP, Global Research and CSO David Altshuler Sold $2. ... GuruFocus.com
12:20PM  Sarepta's FDA rejection could have ripple effect in other Duchenne biotechs American City Business Journals
10:20AM  Surging Earnings Estimates Signal Upside for Vertex (VRTX) Stock Zacks
08:00AM  FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment Business Wire
Aug-14-19 10:53AM  Top Research Reports: Amazon, Caterpillar, Vertex & More Zacks
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
Aug-13-19 10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
Aug-11-19 10:15AM  Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals Motley Fool
Aug-09-19 01:18PM  The 10 Largest-Cap Growth Stocks Motley Fool
10:31AM  Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up Zacks
Aug-08-19 11:06AM  Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up Zacks
10:54AM  Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss Zacks
08:41AM  Is Vertex (VRTX) a Great Growth Stock? Zacks
04:02AM  3 Strong Buy Healthcare Stocks Insiders Are Buying Now TipRanks
Aug-07-19 07:54PM  Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy American City Business Journals
Aug-06-19 09:35PM  Edited Transcript of VRTX earnings conference call or presentation 31-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
07:15PM  Vertex Pharmaceuticals Inc (VRTX) EVPChief Commercial Officer Stuart A Arbuckle Sold $657,132 ... GuruFocus.com
10:04AM  Vertex Has "Significant Financial Firepower" Motley Fool
Aug-05-19 09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Aug-04-19 10:03AM  Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact? Motley Fool
Aug-03-19 01:15AM  Top Biotech Stocks for February 2019 Investopedia
Aug-02-19 10:25AM  Vertex Pharmaceuticals Stock Soared on a Strong Earnings Report Barrons.com
Aug-01-19 04:35PM  US Stocks Deep in the Red on Thursday GuruFocus.com +7.60%
12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
11:23AM  Vertex Pharmaceuticals Inc (VRTX) Q2 2019 Earnings Call Transcript Motley Fool
09:21AM  Proteostasis (PTI) to Post Q2 Earnings: What's in Store? Zacks
Jul-31-19 05:25PM  Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates Zacks
05:07PM  Vertex Posts A Beat-And-Raise As Each Drug Tacks On Growth Investor's Business Daily
04:01PM  Vertex Reports Second-Quarter 2019 Financial Results Business Wire
02:30PM  Vertex Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
12:06PM  Vertex Earnings, Revenue Beat in Q2 Investing.com
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics, as well as a strategic collaboration with Ribometrix, Inc. to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parini MichaelEVP, CL&AOOct 17Option Exercise122.454,250520,41339,253Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 17Sale177.804,250755,65035,003Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 14Option Exercise90.292,125191,86637,128Oct 16 04:14 PM
Parini MichaelEVP, CL&AOOct 14Sale174.062,125369,88535,003Oct 16 04:14 PM
Bhatia Sangeeta N.DirectorOct 02Option Exercise126.517,088896,67613,628Oct 04 04:11 PM
Tatsis OuraniaSVP, CROOct 02Sale167.6944474,4547,252Oct 03 04:25 PM
Bhatia Sangeeta N.DirectorOct 02Sale166.808,3791,397,6405,249Oct 04 04:11 PM
Tatsis OuraniaSVP, CROOct 01Sale169.1118831,7937,696Oct 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Option Exercise103.2512,5011,290,68136,212Aug 20 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Sale186.3812,5012,329,97631,553Aug 20 04:30 PM
MCGLYNN MARGARET GDirectorAug 13Option Exercise81.5410,000815,40014,124Aug 15 04:11 PM
MCGLYNN MARGARET GDirectorAug 13Sale185.0010,0001,850,0004,124Aug 15 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Option Exercise131.892,125280,26635,365Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Sale181.892,125386,51633,240Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Option Exercise86.521,553134,36633,793Aug 06 04:41 PM
Parini MichaelEVP, CL&AOAug 05Option Exercise86.522,330201,59237,333Aug 06 04:43 PM
Parini MichaelEVP, CL&AOAug 05Sale175.282,330408,39935,003Aug 06 04:43 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Sale176.441,553274,01132,240Aug 06 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise91.052,155196,21334,395Aug 06 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale177.782,155383,11632,240Aug 06 04:41 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86637,128Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 12Sale175.272,125372,45535,003Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41339,253Jul 09 04:49 PM
Parini MichaelEVP, CL&AOJul 05Sale179.114,250761,23935,003Jul 09 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Option Exercise131.892,125280,26635,365Jun 20 04:53 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Sale181.892,125386,51633,240Jun 20 04:53 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Option Exercise77.3156,0304,331,679162,317Jun 20 04:43 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Sale175.3956,0309,827,054106,287Jun 20 04:43 PM
Bhatia Sangeeta N.DirectorJun 03Sale167.08720120,2986,540Jun 04 04:08 PM
Parini MichaelEVP, CL&AOMay 30Sale173.00707122,31135,625May 06 04:08 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Option Exercise77.31113,4328,769,428219,719May 28 05:45 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Sale175.10113,43219,861,943106,287May 28 05:45 PM
Sachdev AmitEVP, CROMay 15Sale165.416110,09033,416May 17 04:37 PM
Silva Paul MSVP & ControllerMay 15Sale165.4116126,63117,759May 17 04:31 PM
Parini MichaelEVP, CL&AOMay 15Sale165.418313,72935,003May 17 04:29 PM
Kewalramani ReshmaEVP and CMOMay 15Sale165.4124139,86413,736May 17 04:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale165.4113322,00033,240May 17 04:18 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale165.419115,05231,553May 17 04:16 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Option Exercise77.3133,0582,555,714136,953May 08 04:10 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Sale175.0133,0585,785,504106,195May 08 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Option Exercise86.521,553134,36634,793May 06 04:06 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,329201,50537,332May 06 04:08 PM
Parini MichaelEVP, CL&AOMay 03Sale172.061,622279,07435,003May 06 04:08 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Sale172.391,553267,72333,240May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Option Exercise91.052,155196,21335,395May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Sale169.272,155364,76833,240May 06 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Option Exercise77.3110,480810,209116,375May 03 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Sale175.0810,4801,834,826106,195May 03 04:06 PM
Parini MichaelEVP, CL&AOApr 16Option Exercise111.736,375712,27939,253Apr 18 04:12 PM
Parini MichaelEVP, CL&AOApr 16Sale181.996,3751,160,16635,003Apr 18 04:12 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 15Sale181.755,6241,022,14833,240Apr 17 04:30 PM
LEIDEN JEFFREY MCEO & PresidentFeb 19Sale186.9820,9973,926,113106,195Feb 21 04:24 PM
Kewalramani ReshmaEVP and CMOFeb 19Sale186.941,488278,16313,736Feb 21 04:22 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 19Sale187.005,6241,051,71631,553Feb 21 04:21 PM
Silva Paul MSVP & Interim CFOFeb 19Sale186.972,812525,74717,759Feb 21 04:27 PM
Parini MichaelEVP, CL&AOFeb 19Sale186.985,6241,051,58535,003Feb 21 04:26 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale180.24111,43120,083,804127,192Feb 13 04:39 PM
Sachdev AmitEVP, CROFeb 11Sale180.0635,0956,319,21640,165Feb 13 04:40 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale180.2232,9565,939,18837,177Feb 13 04:36 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 11Sale180.2133,0735,959,96938,864Feb 13 04:37 PM
Silva Paul MSVP & Interim CFOFeb 11Sale180.164,215759,36720,571Feb 13 04:27 PM
Silva Paul MSVP & Interim CFOFeb 06Option Exercise91.051,289117,36313,938Feb 07 04:04 PM
Silva Paul MSVP & Interim CFOFeb 06Sale193.001,289248,77712,649Feb 07 04:04 PM
Parini MichaelEVP, CL&AOFeb 04Option Exercise86.522,330201,59238,489Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Option Exercise88.494,126365,11741,443Feb 06 04:46 PM
Silva Paul MSVP & Interim CFOFeb 04Option Exercise86.5280969,99516,896Feb 06 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Option Exercise99.977,959795,65754,711Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Option Exercise88.904,097364,23548,817Feb 06 04:51 PM
Sachdev AmitEVP, CROFeb 04Sale186.8612,7222,377,29638,037Feb 06 04:51 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Sale186.2018,3093,409,08236,402Feb 06 04:50 PM
Silva Paul MSVP & Interim CFOFeb 04Sale187.024,247794,27312,649Feb 06 04:49 PM
LEIDEN JEFFREY MCEO & PresidentFeb 04Sale186.3532,2506,009,682124,865Feb 06 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Sale189.194,126780,59839,113Feb 06 04:46 PM
Parini MichaelEVP, CL&AOFeb 04Sale189.192,330440,81336,159Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Option Exercise131.892,125280,26641,238Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Option Exercise131.892,125280,26648,877Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Option Exercise155.573,668570,63143,277Jan 24 04:47 PM
Parini MichaelEVP, CL&AOJan 22Sale195.003,668715,26039,609Jan 24 04:47 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Sale193.482,125411,14546,752Jan 24 04:46 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Sale193.482,125411,14539,113Jan 24 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Option Exercise155.701,223190,42140,336Jan 22 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Sale194.621,223238,02039,113Jan 22 04:07 PM
Silva Paul MSVP & Corp ControllerJan 17Option Exercise90.623,007272,48217,376Jan 18 04:18 PM
Silva Paul MSVP & Corp ControllerJan 17Sale190.623,007573,18216,087Jan 18 04:18 PM
Parini MichaelEVP, CL&AOJan 14Option Exercise90.292,125191,86641,734Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 14Sale186.712,125396,75939,609Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 04Option Exercise122.454,250520,41343,859Jan 07 04:02 PM
Parini MichaelEVP, CL&AOJan 04Sale165.904,250705,07539,609Jan 07 04:02 PM
SACHS BRUCE IDirectorDec 06Option Exercise34.2410,000342,40023,011Dec 07 04:06 PM
Silva Paul MSVP & Corp ControllerDec 03Option Exercise86.5280969,99516,896Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerDec 03Sale186.52809150,89516,087Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerNov 15Sale163.75121,96516,087Nov 19 05:52 PM
Parini MichaelEVP, CL&AONov 15Sale163.759014,73839,609Nov 19 05:47 PM
Sachdev AmitEVP, CRONov 15Sale163.75619,98946,662Nov 19 05:34 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale163.75294,74946,752Nov 19 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale163.7510016,37539,113Nov 19 05:23 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
open in yahoo | open in reuters | open in google